TMS Treatment for Depression in the National Health Service (TDEP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02016456 |
Recruitment Status :
Completed
First Posted : December 20, 2013
Last Update Posted : September 1, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Depression | Device: Theta-Burst Stimulation Device: High frequency stimulation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 29 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | An Evaluation of Transcranial Magnetic Stimulation in the National Health Service |
Study Start Date : | October 2014 |
Actual Primary Completion Date : | August 2017 |
Actual Study Completion Date : | August 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Theta-Burst Stimulation
Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
|
Device: Theta-Burst Stimulation
At 80% motor threshold determined using single pulse stimuli. Depending on the hemisphere determined by connectivity analysis and neuronavigation in each individual, either continuous (left prefrontal) or intermittent (right prefrontal) train of pulses will be delivered. |
Active Comparator: High Frequency stimulation
High frequency Transcranial Magnetic Stimulation using the standard protocol for depression, on left dorsolateral prefrontal cortex.
|
Device: High frequency stimulation
Left prefrontal stimulation. 120% motor threshold with a pulse sequence of 10 Hz for 4 seconds, followed by a 26 second quiet period. Treatment will last for a total of 37.5 minutes this is a total of 3,000 pulses |
- Proportion of responders defined as subjects with 50% reduction in the 17-item Hamilton Depression Scale Score [ Time Frame: 4 weeks ]
- Mean change in Beck Depression Inventory scores [ Time Frame: 4 weeks ]
- Change in processing speed (using modified digit-symbol test) scores [ Time Frame: 4 weeks and 3 months ]
- Change in Clinical Global Impression scores [ Time Frame: 4 weeks and 3 months ]
- Change in Social and Occupational Functioning Assessment scores [ Time Frame: 4 weeks and 3 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of depressive disorder (DSM-IV)
- Diagnosis of treatment resistance (at least stage 1 as defined by Thase & Rush, 1997 for depression)
- Female or male between 18 and 70 years
Exclusion Criteria:
- History of Bipolar disorder
- Clinically relevant neurological comorbidity such as brain neoplasm, cerebral vascular events, epilepsy, neurodegenerative disorders, prior brain surgery
- Metal objects in and around body that cannot be removed
- Pregnancy
- Cardiac pacemaker or implanted medication pump
- Major unstable medical illness
- Change in prescribed medication in the 2 weeks preceding the start of TMS trial
- Current alcohol/stimulant dependence with propensity for toxic/withdrawal seizures

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02016456
United Kingdom | |
Neuromodulation Unit, Nottinghamshire Healthcare NHS Trust | |
Nottingham, England, United Kingdom, NG2 7UH |
Principal Investigator: | Sudheer Lankappa, MRCPsych | Nottinghamshire Healthcare NHS Trust |
Responsible Party: | Sudheer Lankappa, Consultant Psychiatrist, Institute of Mental Health Nottingham |
ClinicalTrials.gov Identifier: | NCT02016456 |
Other Study ID Numbers: |
AMH/021213 |
First Posted: | December 20, 2013 Key Record Dates |
Last Update Posted: | September 1, 2017 |
Last Verified: | August 2017 |
Transcranial Magnetic Stimulation Neuronavigation Magnetic Resonance Imaging |
Depression Depressive Disorder Behavioral Symptoms Mood Disorders Mental Disorders |